Russian Move To Limit Medtech Imports Could Harm Domestic Innovation
This article was originally published in Clinica
Executive Summary
Import substitution and tendering practices that put non-Russian/EAEU-based medtech manufacturers at a disadvantage were introduced under Russian Resolution 102 in February 2015. Clinica asked executives from IMEDA, Russia’s International Medical Device Manufacturers Association, what effect this will have on market supply, patient care and innovation
You may also be interested in...
Russia's Medtech Looks For Chain Reaction After Philips Partnership Deal
Russia's health care sector has been under strain, suffering budgets cuts and repercussions from the ongoing sanctions. In the midst of this, plans to reinforce the local medtech industry received a boost recently when global top 10 manufacturer Philips Healthcare committed funds to embarking on new R&D locally and to further partnerships in Russia.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.